Kite’s Acquisition of Tmunity

Cooley advised Tmunity on the deal. Tmunity, a clinical-stage biotechnology company, announced its agreement to sell to Kite, a global biopharmaceutical company.  The acquisition will provide...

Standard 1 Year Membership Required

You must be a Standard 1 Year member to access this content.

Join Now

Already a member? Log in here

Vaxcyte’s $690 Million Public Offering

Cooley advised Vaxcyte, while Latham & Watkins represented the underwriters on the offering. Vaxcyte, a clinical-stage vaccine innovation company, announced its underwritten public offering of common stock and...

Standard 1 Year Membership Required

You must be a Standard 1 Year member to access this content.

Join Now

Already a member? Log in here

Blueprint Medicines Corporation’s Financing Collaborations with Sixth Street and Royalty Pharma

Goodwin Procter advised Blueprint Medicines Corporation on the deal while Cooley represented Sixth Street. Blueprint Medicines Corporation (NASDAQ: BPMC) announced its strategic financing collaborations with Sixth...

Standard 1 Year Membership Required

You must be a Standard 1 Year member to access this content.

Join Now

Already a member? Log in here